Review examines Neffy’s safety and efficacy in delivering epinephrine, suggesting potential improvements in treatment.
Anaphylaxis is a rapid-onset, potentially fatal allergic reaction requiring prompt administration of epinephrine. Until recently, epinephrine autoinjectors have dominated emergency treatment, but challenges, such as needle phobia, improper use, and poor carriage rates, reduce their real-world efficacy. Neffy (ARS-1; epinephrine nasal spray) introduces a needle-free, intranasal route for epinephrine delivery. This review examines the clinical evidence, pharmacological profile, indications, and safety data for Neffy and discusses implications for clinical practice.
No takes yet. Share an insight, caveat, or question.
Chittoria et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: